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ABSTRACT
Objective Deregulation of the Wnt signalling pathway by
mutations in the Apc or b-catenin genes underlies
colorectal carcinogenesis. As a result, b-catenin
stabilises, translocates to the nucleus, and activates
gene transcription. Intestinal tumours show
a heterogeneous pattern of nuclear b-catenin, with the
highest levels observed at the invasion front. Activation
of receptor tyrosine kinases in these tumour areas by
growth factors expressed by surrounding stromal cells
phosphorylate b-catenin at tyrosine residues, which is
thought to increase b-catenin nuclear translocation and
tumour invasiveness. This study investigates the
relevance of b-catenin tyrosine phosphorylation for Wnt
signalling and intestinal tumorigenesis in vivo.
Design A conditional knock-in mouse model was
generated into which the phospho-mimicking Y654E
modification in the endogenous b-catenin gene was
introduced.
Results This study provided in vivo evidence that
b-cateninE654 is characterised by reduced affinity for
cadherins, increased signalling and strongly increased
phosphorylation at serine 675 by protein kinase A (PKA).
In addition, homozygosity for the b-cateninE654 targeted
allele caused embryonic lethality, whereas
heterozygosity predisposed to intestinal tumour
development, and strongly enhanced Apc-driven
intestinal tumour initiation associated with increased
nuclear accumulation of bcatenin. Surprisingly, the
expression of b-cateninE654 did not affect histological
grade or induce tumour invasiveness.
Conclusions A thus far unknown mechanism was
uncovered in which Y654 phosphorylation of b-catenin
facilitates additional phosphorylation at serine 675 by
PKA. In addition, in contrast to the current belief that
b-catenin Y654 phosphorylation increases tumour
progression to a more invasive phenotype, these results
show that it rather increases tumour initiation by
enhancing Wnt signalling.
Most cases of sporadic colorectal cancer are initi-
ated by activation of the Wnt/becatenin signalling
pathway through mutations in either adenomatous
polyposis coli (APC) or b-catenin itself. b-Catenin is
involved in cell adhesion through forming
cadherinecatenin complexes as well as in gene
transcription through binding to TCF/LEF as a
co-activator of transcription. N-terminal serine/
threonine phosphorylation of b-catenin by GSK3
and CK1 targets it for degradation, whereas inac-
tivation of APC leads to cytoplasmic accumulation
of b-catenin, which eventually translocates to the
nucleus to activate transcription.1 This model
implies that nuclear accumulation of b-catenin
should earmark all APC-deficient cells; however,
a heterogeneous pattern of nuclear b-catenin is
observed in APC-driven intestinal tumours.2 3 This
indicates that additional mechanisms are involved
in b-catenin nuclear translocation and in the regu-
lation of Wnt signalling activation by modulating
b-catenin.4 Nuclear b-catenin staining strongly
correlates with tumour size and the grade
of dysplasia, with the highest levels of nuclear
b-catenin at the invasion fronts of adenocarci-
nomas.2 3 For these reasons, obtaining a better
understanding of the processes that control nuclear
accumulation of b-catenin during tumour progres-
sion is of great clinical relevance.
< Additional materials are
published online only. To view
these files please visit the
journal online (http://gut.bmj.
com).
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Significance of this study
What is already known about this subject?
< Increased Wnt/b-catenin signalling underlies the
initiation and progression of colorectal cancer.
< Receptor tyrosine kinases are activated in
colorectal cancer by growth factors coming
from the tumour stroma.
< Receptor tyrosine kinases can phosphorylate
tyrosine 654 of b-catenin.
What are the new findings?
< We provide in-vivo evidence that tyrosine 654
phosphorylated b-catenin shows reduced inter-
action with cadherins, increased signalling and
strongly increased phosphorylation at serine 675
by protein kinase A (PKA).
< Expression of tyrosine 654 phosphorylated
-catenin predisposes to intestinal tumour develop-
ment in mice.
< Tyrosine 654 phosphorylation of b-catenin
strongly enhances Apc-driven intestinal tumour
initiation, but not progression to a more
aggressive tumour phenotype.
How might it impact on clinical practice in the
foreseeable future?
< Our results suggest that therapy targeted at the
tumour stroma, tyrosine kinases and PKA, may
serve an efficient treatment strategy for patients
with intestinal or other cancers involving active
Wnt signalling.
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One of the mechanisms affecting Wnt signalling is b-catenin
tyrosine (Y) phosphorylation by active receptor tyrosine kinases
(RTK).5 6 Tumour cells as well as stromal cells in the tumour
microenvironment secrete growth factors that activate their
cellular receptors expressed at the plasma membrane of tumour
cells. In a large number of cancers, including colorectal cancer,
overexpression of RTK or expression of structurally altered RTK
results in increased growth factor signalling.7 Upon activation of
RTK, various downstream adaptor and signalling molecules are
recruited and phosphorylated, thus triggering the activation of
different intracellular pathways, among which are the RAS/
MAPK and the PI3K/AKT pathways.7 In addition, RTK activa-
tion leads to tyrosine phosphorylation of b-catenin affecting its
functions in cell adhesion and signalling. In particular, phos-
phorylation of b-catenin residue Y654 results in its release from
cadherins and an increase in TCF-mediated transcriptional
activity.8e11 Altogether, these results suggest that b-catenin
Y654 phosphorylation balances its role between cell adhesion
and Wnt signalling.5 6 8 As such, enhanced Y654 phosphoryla-
tion of b-catenin is believed to increase cell migration and induce
an invasive behaviour of tumour cells, although functional
evidence for the latter is still lacking.
To determine the relevance of b-catenin Y654 phosphorylation
for Wnt signalling and intestinal tumorigenesis in vivo, we have
generated a conditional knock-in mouse model in which we
introduced the phospho-mimicking Y654E modification in the
endogenous b-catenin gene. The resulting b-cateninE654 protein is
characterised by reduced affinity for cadherins and increased
transcriptional activity. We show that while homozygosity for
the b-cateninE654 targeted modification results in embryonic
lethality, heterozygosity for b-cateninE654 is sufficient to initiate
intestinal tumour formation and to increase Apc-driven intes-
tinal tumour initiation. Importantly, these phenotypes are not
accompanied by an increased migratory phenotype, showing
that, in contrast to current belief, b-catenin Y654 phosphoryla-
tion by itself is not sufficient to impose an invasive phenotype
onto cells. Moreover, we uncovered a thus far unknown mech-
anism in which Y654 phosphorylation of b-catenin facilitates
additional phosphorylation at serine (S) 675 by protein kinase A
(PKA). Taken together, we provide in-vivo evidence that
b-catenin Y654 phosphorylation enhances Wnt signalling and
thereby increases intestinal tumour formation.
MATERIALS AND METHODS
Mouse strains
The mouse strains (C57BL/6J genetic background) used in this
study were: Apc+/15lox, Apc+/1572T, Apc+/1638N, Fabpl-Cre, CAG-
Cre and CAG-Flp.12e17 All mice were generated, bred and
maintained under specific pathogen-free conditions at the
animal facility of the Erasmus Medical Centre (Rotterdam,
The Netherlands). All animal experiments were approved by the
Institute’s Animal Ethics Committee and were carried out in
accordance with Dutch and international legislation.
Generation of conditional b-cateninY654E knock-in mice
A b-catenin targeting vector was constructed as described in the
supplementary material available online only. One targeted ES
clone was used to obtain chimeras by injecting C57BL/6J blas-
tocysts and breeding with C57BL/6J mice to produce outbred
heterozygous b-cateninY654/Y654E-fl-neo mice (mixed C57BL/
6J;129Ola background). These mice were mated with either
CAG-Flp or CAG-Cre mice to obtain b-cateninY654/E654-fl and
b-cateninY654/E654 mice, respectively. Mice and embryos were
genotyped as described in the supplementary material, available
online only.
Skeletal preparations and staining
b-cateninY654/E654 mice were backcrossed to a C57Bl6/J genetic
background (seven generations) and interbred. Embryos of E15.5
were harvested, skinned and eviscerated, fixed overnight in 96%
ethanol containing 1% glacial acetic acid. Cartilage was stained
overnight in 0.5 mg/ml Alcian Blue. Soft tissue was dissolved in
1.5% potassium hydroxide for 3 h. Bone was then stained
overnight in 0.15 mg/ml Alizarin Red. Embryos were destained
in 0.5% potassium hydroxide/20% glycerol for 3 days.
Intestinal tumour analysis
The entire intestines were isolated, opened longitudinally,
washed in phosphate-buffered saline and fixed overnight at 48C
in 10% phosphate-buffered formalin. The size and location of
tumours was determined using a dissection microscope.
Tissue processing and immunohistochemical analysis
Fixed intestinal tumours and embryos (4% paraformaldehyde)
were routinely embedded in paraffin. Sections were stained by
haematoxylin eosin for routine histology. All tumours were
histologically classified according to previously reported
criteria.18 Primary and secondary antibodies employed for
immunohistochemical analysis are depicted in the supplemen-
tary material, available online only. Proliferation rates were
quantified by determining the average percentage of phospho-
Histone-H3 positive cells in five microscopic fields per tumour.
Percentages of cells positive for nuclear b-catenin were deter-
mined as an average of five microscopic fields per tumour, and
were scaled in three groups, less than 25%, 25e50% or over 50%
of tumour cells with nuclear b-catenin.
Allelic imbalance analysis
Tumour (T) and normal (N) tissue was microdissected from
three paraffin sections and DNA was isolated as described
previously.15 PCR were performed using the geno654-F and
geno654-R primers (supplementary material, available online
only) to show the presence of the Y654 and E654 alleles.
Cell culture, transient transfection and treatments
b-cateninY654/E654 mice were backcrossed to a C57BL/6J genetic
background (seven generations) and interbred. Mouse embryonic
fibroblasts (MEF) were isolated from embryos of E13.5e15.5 and
cultured as previously described.19 Cos-1 cells were cultured in
Dulbecco’s modified essential medium complemented with 1%
P/S and 10% fetal bovine serum at 378C, 5% carbon dioxide.
MEF and Cos-1 cells were transfected using FuGENE HD
(Roche) or Polyethylenimine Max (PEI; Polysciences, Inc,
Eppelheim, Germany), respectively. Plasmids used in Cos-1 cells
were pEGFP-C1 GFP-b-catenin expression vectors, in which the
Y654E and Y654F mutations were introduced by site-directed
mutagenesis. Cells were treated with 25 mM H89 (Enzo Life
Sciences, Lausen, Switzerland) for 24 h or 50 mM forskolin
(Merck, Whitehouse Station, NJ, USA) for 1 h.
b-Catenin reporter assay
b-Catenin reporter assays were performed in MEF using the
Wnt-responsive element-luciferase reporter kindly provided by
Dr Georges Rawadi (Galapagos, Paris, France) for which we
generated a mutant-responsive element-luciferase variant.
Tk-Renilla was used as a control for transfection efficiency. After
transfection, cells were stimulated for 24 h with 25% of
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L-control or L-Wnt3A-conditioned medium.20 Luciferase activi-
ties were measured using the dual-luciferase reporter assay
system (Promega, Madison, WI, USA) and a LUMIstar lumin-
ometer according to the manufacturer ’s protocol.
Immunoprecipitation and fluorescent immunoblotting
Cell lysates for co-immunoprecipitation (coIP) were generated
using E1A buffer (50 mM Tris pH 7.5, 250 mM NaCl, 5 mM
ethylene diammine tetraacetic acid, 0.1% Nonidet-P40, complete
protease inhibitor cocktail (Roche, Basel, Switserland), 1 mM
sodium vanadate (Na3VO4), 1 mM phenyl-methylsulphonyl
fluoride). Protein concentrations were determined using Quick-
start Bradford (Bio-Rad, Hercules, CA, USA) according to the
manufacturer ’s protocol; 100 mg of protein was incubated with
0.25 mg b-catenin antibody (BD Transduction Laboratories,
Franklin Lakes, NJ, USA) overnight at 48C and precipitated using
protein G Sepharose beads (GE Healthcare, Chalfont St Giles,
UK). Precipitated proteins were resuspended in 100 ml Laemmli
sample buffer. Fluorescent Odyssey immunoblotting (LI-COR
Biosciences, Lincoln, NE, USA) was performed for these immu-
noprecipitated proteins and total lysates as described in the
supplemental materials.
RESULTS
Homozygosity for b-cateninE654 results in embryonic lethality
We generated a conditional b-catenin knock-in mouse model in
which, following Cre activity, exons 12e15 enclosing Y654 will
be replaced by the same exons containing a glutamic acid (E) at
residue 654, that is b-cateninY654/Y654E-fl mice (figure 1A).
Heterozygous b-cateninY654/Y654E-fl mice were bred with CAG-Cre
mice to obtain heterozygous b-cateninY654/E654 mice, expressing
both the b-cateninY654 and b-cateninE654 alleles at equal tran-
scriptional levels (see supplementary figure S1A, available online
only). These animals were interbred to obtain several indepen-
dent MEF lines expressing either wild-type b-catenin (YY),
b-cateninE654 (EE), or expressing both forms of b-catenin (YE) at
endogenous levels. Using both control and Wnt3A ligand-stim-
ulated conditions, we measured a significant increase (p<0.005)
in b-catenin-mediated transcription in MEF expressing b-cate-
ninE654 (figure 1B), indicating that the b-catenin Y654E modifi-
cation increases Wnt signalling in vivo.
Interbreeding of b-cateninY654/E654 animals showed that
homozygosity leads to embryonic lethality around birth (see
supplementary table S1, available online only). Macroscopic
analysis of whole embryos at E10.5 revealed that homozygous
b-cateninE654/E654 embryos had smaller head sizes and unfused
facial processes, both typical features of anterior truncation
(figure 2A). We did not observe any additional deformities in the
remainder of the embryos, nor could we observe malformations
in heterozygous b-cateninY654/E654 embryos (figure 2A). Sagittal
sections of E12.5 homozygous b-cateninE654/E654 embryos showed
that the most rostral regions of the head were severely under-
developed (figure 2B). The primordia of the nasal capsule and
upper jaw were highly abnormal or absent, whereas the devel-
opment of mandible and tongue was only mildly affected.
Skeletal stainings of E15.5 embryos showed that the dermal
skull roof as well as the upper jaw were virtually absent, while
the lower jaw (Meckel’s cartilage and dentaries) appeared to be
near normal (figure 2C). These data indicate that the increase in
Wnt signalling resulting from the expression of b-cateninE654
causes an embryonic lethal phenotype similar to phenotypes
observed in other Apc and Wnt-related mouse models.21e23
Despite reduced affinity for cadherins, b-cateninE654 is still
localised at the plasma membrane
Previously reported transient overexpression experiments
suggested that the interaction between b-catenin and cadherins
was reduced by the Y654E modification,9e11 resulting in
a switch of b-catenin from the membranous adhesion pool to
the nuclear signalling pool. To investigate whether this was also
Figure 1 Generation of
b-cateninY654/E654 mice. (A) A
Y654E-fl-neo allele was generated by
homologous recombination in ES cells,
using the targeting vector described in
the supplementary material, available
online only. Breeding with CAG-Flp mice
removes the Neo cassette resulting in the
Y654E-fl allele. By breedingwith CAG-Cre
or Fapbl-Cre mice, the original exons
12e15 were removed, ending up with
the E654 allele. (B) b-Catenin reporter
assays were performed to measure
b-catenin-mediated transcription in
mouse embryonic fibroblasts (MEF)
expressing b-cateninY654/Y654 (YY),
b-cateninY654/E654 (YE) or
b-cateninE654/E654 (EE). Following
transfection, b-catenin signalling was
induced by stimulating MEF with Wnt3A
ligand. Wnt-responsive element/
mutant-responsive element ratios were
measured in three individual experiments
in duplo, and averaged. *p<0.005,
Student’s t-test. Numbers
between brackets refer to the
number of independent cell lines used
for each genotype. Cre, Cre recombinase; FLP,
flippase recombinase; FRT, FLP recombinase
target; LoxP, Cre recombinase target.
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the case for b-cateninE654 at endogenous levels, we performed
coIP experiments using our MEF lines. Protein expression levels
of the b-cateninE654 variant were similar to b-cateninY654, and
we observed no clear differences in the expression of cadherins
between the different MEF lines (figure 3A). However, the
interaction of b-cateninE654 with cadherins was clearly impaired
compared with b-cateninY654, suggesting that the involvement
of b-cateninE654 in adhesion junctions is reduced (figure 3A,B).
Although the reduced interaction between b-cateninE654 and
cadherins suggested that cell adhesion would be affected, the
formation of epithelial structures in b-cateninE654/E654 embryos
was not impaired, and a normal expression pattern for
E-cadherin could be detected in all epithelia (figure 3C). Notably,
b-catenin was also detected at the plasma membrane at equal or,
at most, slightly reduced levels in epithelia of b-cateninE654/E654
embryos, and could not be observed in the cytosol or nuclei of
epithelial cells (figure 3D), suggesting that the Y654E modifica-
tion is not sufficient to shift b-catenin from the plasma
membrane to the nucleus, at least not at levels detectable with
immunohistochemistry. Overall, these data indicate that
increased Wnt signalling by the expression of b-cateninE654
causes anterior malformations during embryonic development,
without affecting the formation of epithelial structures.
Heterozygous b-cateninY654/E654 mice develop intestinal
adenomas
As b-cateninE654 increases Wnt signalling, we questioned
whether the expression of b-cateninE654 would predispose to
tumour development in vivo. Therefore, we examined hetero-
zygous b-cateninY654/E654 mice and wild-type littermates at the
age of 16-18 months for abnormalities with a specific focus on
lesions typically developing in Apc mutant models, that is
intestinal and mammary tumours, cutaneous cysts and
desmoids.13e15 19 24 25 Fourteen tumours were identified in the
duodenum or jejunum of 11 out of 29 (38%) heterozygous
animals compared with none out of nine wild-type littermates
(p¼0.038) (figure 4A). Fifty per cent of these intestinal tumours
were histologically identified as gastrointestinal intraepithelial
neoplasia/adenoma, 21% as adenoma and 29% as dysplastic
adenoma/carcinoma in situ according to previously described
criteria.18 We did not observe any predisposition for other lesions
such as cysts, desmoids or mammary tumours.
Immunohistochemical analyses revealed that b-catenin
expression was strongly reduced at the plasma membrane of
tumour cells compared with normal intestinal epithelial cells
(figure 4B); however, nuclear b-catenin could not be observed
(figure 4B). Allelic imbalance analysis revealed that both the
wild-type (Y654) and modified (E654) alleles were retained in all
nine intestinal tumours tested (figure 4C). Although nuclear
b-catenin could not be observed in the tumour cells, the
expression of CD44 and cyclin-D1, both canonical b-catenin
target genes,26 was increased in these tumours (figure 4B). These
results suggest that the expression of b-cateninE654 predisposes
to intestinal tumour formation associated with increased Wnt
signalling.
Embryonic lethality of compound heterozygous b-catenin;Apc
mice
To investigate the effect of b-cateninE654 on Apc-driven tumour
formation, we bred our b-catenin model with two mutant Apc
knock-in mouse models, that is Apc+/1572T and Apc+/1638N.13e15
However, compound heterozygous b-catenin;Apc animals could
not be obtained from these breedings, indicating that hetero-
zygosity for the Apc1572T or Apc1638N mutations acts syner-
gistically with the heterozygous Y654E modification in b-catenin
to induce an embryonic lethal phenotype (see supplementary
table S2, available online only). Compound heterozygous
b-catenin;Apc embryos showed an anterior truncation phenotype
similar to the one observed in b-cateninE654/E654 embryos (see
supplementary figure S2, available online only). The
Figure 2 Anterior truncation in homozygous b-cateninE654/E654
embryos. (A) Whole embryo pictures at E10.5 showing a severe anterior
truncation phenotype of homozygous b-cateninE654/E654 (EE) embryos
compared to wild-type (YY) and heterozygous b-cateninY654/E654 (YE)
embryos. (B) Haematoxylin eosin stainings of sagittal sections of the
head region of E12.5 embryos. (C) Skeletal stainings of E15.5 embryos.
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telencephalic region of b-cateninY654/E654;Apc+/1638N embryos was
more severely reduced compared with b-cateninY654/E654;Apc+/
1572T embryos. Accordingly, b-cateninY654/E654 embryos in combi-
nation with the Apc1638N mutation were less commonly
detected compared with the ones combined with the Apc1572T
mutation, 11.1% and 29.7%, respectively (see supplementary
table S2, available online only). These results suggest that the
proper development of mice expressing the b-cateninE654 allele in
combination with the Apc1638N allele is more severely affected
compared with the Apc1572T allele, which is probably explained
by our previous observations that Apc1572T retains more residual
b-catenin downregulating activity than Apc1638N.13 19
In conclusion, the lethality observed in these compound
heterozygous embryos indicates that retaining only half the
level of functional Apc is insufficient to counterbalance the
increased propensity of b-cateninE654 to signal to the nucleus,
and confirms our observation that the b-cateninE654 allele
contributes to increased Wnt signalling.
b-CateninE654 increases Apc-driven intestinal tumour formation
Theembryonic lethality of compoundApc;b-cateninmice, described
above, precludes the analysis of tumorigenesis in adult phenotypes.
Therefore, we generated intestinal-specific Apc;b-catenin double
mutant mice to determine whether b-cateninE654 contributes to
Apc-driven intestinal tumorigenesis. To this aim, we used the
Fabpl-Cre mouse model, which expresses Cre recombinase specifi-
cally in the ileum, cecum and large intestine.16 We bred Fabpl-Cre
mice with conditional b-cateninY654/Y654E-fl-neo mice and with
conditional Apc+/15lox mice12 in order to generate compound
heterozygous Apc+/D15;b-cateninY654/E654mice expressing both Apc
and b-catenin variants specifically in the intestines. At 8 months of
age, Apc+/D15;b-cateninY654/E654 mice (from here on Apc;YE mice)
showed a significant increase in tumour number compared with
Apc+/D15;b-cateninY654/Y654mice (fromhere onApcmice) (p¼0.013).
Notably, tumour numbers were significantly increased in males
(p¼0.02), but not in females (p¼0.48) (figure 5A). Age-matched
Apc+/+;b-cateninY654/E654 mice (from here on YE mice) and other
control littermates had not developed intestinal tumours. Tumours
of Apcmice were localised predominantly in the ileum, but also in
the cecum and large intestine (figure 5B). Upon additional expres-
sion of the b-cateninE654 variant, the distribution of tumours
was shifted more towards the large intestines, both in males and
females (figure 5B). These data show that heterozygosity for the
b-cateninE654 targeted allele increases Apc-driven intestinal tumour
formation and shifts tumour location.
Because Y654 phosphorylation of b-catenin leads to reduced
interaction with cadherins and increased Wnt signalling, current
belief is that this would result in increased tumour invasiveness.6
To investigate whether b-cateninE654 contributes to Apc-induced
tumour progression in vivo, we determined the histological
grade, size and proliferation rate of tumours from male Apc and
Apc;YE mice. The tumours were histologically classified as
hyperplasia/adenoma, dysplastic adenoma/carcinoma in situ or
adenocarcinoma, but no differences in malignancy could be
observed between both groups (figure 5C). Tumours of Apc;YE
mice were on average smaller compared with tumours from Apc
mice, both for males (p¼0.0001) and females (p¼0.022) (figure
5D and supplementary figure S3A, available online only). Phos-
phoHistone-H3 stainings of size-matched tumours from male
Apc;YEmice showed a slightly although not significant (p¼0.09)
increase in the proliferation rate compared with tumours from
Apc mice (see supplementary figure S3B, available online only).
These results indicate that b-cateninE654 increased Apc-driven
intestinal tumour initiation, but not tumour progression.
Because tumours of Apc+/D15 mice show a clear nuclear
accumulation of b-catenin,12 we hypothesised that the intro-
duction of the Y654E modification in b-catenin would further
increase the percentage of cells showing nuclear b-catenin.
Immunohistochemical analysis revealed that b-catenin was
more predominantly localised in the nuclei of Apc;YE tumours
compared with Apc tumours (figure 5E). Together, this indicates
that b-cateninE654 translocates more readily to the nuclear
signalling pool of Apc-deficient cells in vivo, thereby contributing
to Apc-driven tumour initiation without clearly affecting
tumour invasion and metastasis.
Phosphorylation at b-catenin Y654 facilitates phosphorylation
at S675 by PKA
Xing et al27 described that the armadillo repeat 12 in which Y654
is located forms several H-bonds with the C-tail of b-catenin.
Residues up and downstream of Y654, that is Leu644 and
Phe660, directly interact with residues in the C-tail of b-catenin,
Figure 3 b-cateninE654 in cadherin-catenin complexes. (A) Total endogenous b-catenin was immunoprecipitated from YY, YE and EE mouse
embryonic fibroblasts (MEF). Co-precipitated cadherins were detected by immunoblotting with two individual antibodies (Ncad and PANcad).
Expression levels of b-catenin as well as of cadherins were shown in total lysates (input). (B) Quantification of interaction between b-catenin and
cadherins. The interactions were calculated by correcting the amount of co-precipitated cadherins for the amount of precipitated b-catenin. The
interaction levels were quantified in three individual experiments, and averaged. Numbers between brackets refer to the number of independent cell
lines used for each genotype. (C) Representative E-cadherin immunostaining of bronchial alveoli of a wild-type and homozygous b-cateninE654/E654
embryo (4003). (D) Representative b-catenin immunostaining of epidermis of a wild-type and homozygous b-cateninE654/E654 embryo (4003).
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among which are leucine residues at codons 674 and 678.27 In
between these two leucine residues, another phosphorylation
site of b-catenin is located, that is S675.28 Piedra et al10 have
suggested that the S675-containing C-tail of b-catenin folds
open upon phosphorylation of Y654, due to the negative charge
introduced at armadillo repeat 12. This led us to hypothesise
that, upon phosphorylation of Y654, the S675 becomes available
for additional phosphorylation. Therefore, we determined
the levels of S675-phosphorylated b-catenin in total lysates of
the MEF lines, using an antibody specifically recognising
phosphoS675 b-catenin.29 Notably, phosphoS675 b-catenin
levels were clearly increased in EE-MEF (figure 6A). The same
results were detected in total lysates of b-cateninE654/E654
embryos (figure 6B), and in intestinal tumours from Apc;YEmice
(figure 6C).
S675 is suggested to be a phosphorylation site for PKA.28e30 To
confirm that PKA is the main kinase phosphorylating S675 in
b-cateninE654, we incubated the MEF lines with a PKA inhibitor
(H89) or PKA activator (forskolin). The efficiency of these agents
on PKA activity was confirmed by decreased or increased phos-
phorylation of CREB, a specific PKA substrate (figure 6D,E).
Upon inhibition of PKA, reduced levels of phosphoS675 b-catenin
could be observed in all MEF lines, indicating that PKA is, at
least partly, responsible for S675 phosphorylation of b-catenin
(figure 6D). Upon activation of PKA, phosphoS675 b-catenin
levels were increased in all MEF lines, although proportionally to
a lower extent in the EE-MEF when compared with their wild-
type controls (figure 6E). We could not observe a difference in
PKA activity between the different MEF lines, indicating that
PKA activity is not altered by the expression of b-cateninE654 (see
supplementary figure S4, available online only). Therefore, we
hypothesised that the Y654E modification in b-catenin facilitates
phosphorylation of S675 by PKA.
Next, we transiently transfected Cos-1 cells with vectors
expressing GFP-tagged wild-type b-catenin (Y654) or variants
thereof (E654 and F654). The latter variant mimics dephos-
phorylated Y654, and may therefore retain a closed conforma-
tion of the C-tail.10 Similar to the MEF, phosphoS675 b-catenin
levels were increased for E654 (see supplementary figure S5A and
B, available online only). Notably, the phosphoS675 b-catenin
level of F654 was comparable with Y654 (see supplementary
figure S5A and B, available online only). PhosphoS675 b-catenin
levels were again inhibited by H89, confirming that PKA is
involved in b-catenin S675 phosphorylation (see supplementary
figure S5A and B, available online only). Notably, S675 phos-
phorylation of b-cateninF654 could not be increased to the same
extent as wild-type b-catenin by forskolin, indicating that S675
in b-cateninF654 is less available for phosphorylation by PKA (see
supplementary figure S5C, available online only). From these
data we concluded that Y654 phosphorylation of b-catenin is
not required for but facilitates additional phosphorylation of
S675 by PKA.
DISCUSSION
Increased growth factor signalling activity has been observed in
a large number of cancers, generally associated with poor prog-
nosis. In many cases this is the result of the overexpression of
the receptor or its ligand, whereas in other cases structural
alterations of RTK are present resulting in constitutive kinase
activity.31e34 This increased RTK activity triggers the activation
of various intracellular pathways. Using in-vitro cell culture
systems, various reports have shown that RTK activation also
leads to tyrosine phosphorylation of b-catenin with subsequent
loss of cell adhesion and increased cell motility characteristic of
malignant tumour cells.5 8 Here, we describe the generation and
functional characterisation of a conditional knock-in mouse
model expressing a Y654 modified b-catenin at endogenous
levels, allowing us to discern the relative contribution of
b-catenin Y654 phosphorylation within the complexity of
a developing tumour and organism.
The main consequence of introducing a phospho-mimicking
modification at Y654 of b-catenin, that is b-cateninE654, is its
increased Wnt signalling activity, which is supported by the
nearly twofold increase in b-catenin reporter activity in MEF
solely expressing b-cateninE654. Further support is provided by the
embryonic phenotypes. Increased Wnt signalling caused by
homozygosity for the b-cateninE654 allele resulted in an anterior
truncation phenotype highly similar to that observed in several
other mouse and Xenopus models in which Wnt signalling is
enhanced.21e23 35 Moreover, retaining only half the level of
functional Apc is insufficient to counterbalance the increased
propensity of b-cateninE654 to signal to the nucleus, which can be
concluded from the embryonic lethal phenotype imposed in mice
compound heterozygous for the b-cateninE654 and mutant Apc
alleles. In addition to these embryonic phenotypes, expression of
the b-cateninE654 variant in Apc-mutant intestinal tissue resulted
in enhanced intestinal tumour formation strongly associated
with increased levels of nuclear accumulation of b-catenin,
underscoring the potency of b-cateninE654 to translocate to the
nucleus and increase Wnt signalling in vivo. Notably,
Figure 4 Heterozygous b-cateninY654/E654 mice develop intestinal
tumours. (A) Numbers and percentages of wild-type (YY) and
heterozygous b-cateninY654/E654 (YE) mice that have developed at least
one intestinal tumour at the age of 16e18 months. p Values, Fisher’s
exact test. (B) Haematoxylin eosin staining, and b-catenin, CD44 and
cyclin-D1 immunostainings of a representative intestinal tumour of a
b-cateninY654/E654 mouse. Membranous b-catenin levels were strongly
reduced in tumour cells compared with normal intestinal epithelial cells,
while no increase in cytoplasmic/nuclear b-catenin could be observed.
The expression of both CD44 and cyclin-D1 was increased in tumour
cells. Lower panels are higher magnifications (4003) of the boxes
indicated in the upper panels (1003). (C) Allelic imbalance analysis
revealed no loss of either the Y654 or E654 alleles in intestinal tumours
of b-cateninY654/E654 mice investigated. N, normal tissue, T, tumour
tissue.
Gut 2011;60:1204e1212. doi:10.1136/gut.2010.233460 1209
GI neoplasia
 group.bmj.com on August 31, 2011 - Published by gut.bmj.comDownloaded from 
heterozygosity for the targeted b-cateninE654 allele predisposed to
intestinal tumours confirming the tumour-promoting potential
of b-catenin modified by Y654 phosphorylation. The tumour
phenotype in these mice showed a low penetrance and late onset,
indicating that additional events are required to drive intestinal
tumorigenesis sufficiently.
The increased signalling activity of b-cateninE654 can partly be
explained by the strong enhancement of PKA-induced phos-
phorylation of S675, for which it has been shown to increase
Wnt signalling by recruiting transcriptional co-activators.28e30 36
A second proposed mechanism for increased Wnt signalling is
the reduced affinity of b-cateninE654 for cadherins leading to an
increased cytoplasmic pool, thereby putting more pressure on
the b-catenin destruction complex to control signalling levels
properly.9e11 Our data support this concept, as we have
observed a nearly 10-fold reduction in the binding affinity of
b-cateninE654 for cadherins. However, despite this reduced
affinity, b-cateninE654 localises at the plasma membrane in
epithelia of homozygous b-cateninE654/E654 embryos, suggesting
that b-cateninE654 is still incorporated in adherens junctions in
vivo. In line with this, Tominaga et al37 previously reported that
cells expressing exogenous b-cateninE654 at endogenous levels
retained their adhesive capacity similar to cells transfected with
wild-type b-catenin. Therefore, we conclude that although Y654
phosphorylated b-catenin has a reduced affinity for cadherins, it
is still considerably involved in the regulation of cell adhesion.
Despite the fact that b-catenin Y654 phosphorylation results
in a reduced interaction with cadherins and increased gene
transcription, no obvious cytoplasmic or nuclear localised
b-catenin could be observed in epithelia of homozygous b-cate-
ninE654/E654 embryos using immunohistochemistry. In intestinal
tumours of Apc;YE mice, increased nuclear localised b-catenin
could, however, be observed, indicating that b-cateninE654 shifts
more readily to the nuclear signalling pool in the absence of
a functional degradation complex. The strong increase in signal-
ling activity that we observed when cells are exposed to Wnt3a
ligand shows that b-cateninE654 is still efficiently targeted for
degradation. Together, this implies that, although Wnt signalling
is increased, nuclear levels of b-catenin upon C-terminal
phosphorylation are too low to be detected with immunohisto-
chemistry, and become more apparent when the destruction
complex is either mutated such as in Apc mutant colorectal
tumours, or is temporarily inhibited by extracellular Wnt signals
such as is the case in anterior embryonic development.
Because of its dual role in cell adhesion and Wnt signalling,
Y654 phosphorylation of b-catenin has been implicated in the
acquisition of an invasive phenotype of tumour cells.6 According
to this model, colorectal tumour cells exposed to high levels of
growth factor signalling coming from the tumour stroma induce
tyrosine phosphorylation of b-catenin, resulting in reduced cell
adhesion and increased nuclear signalling, leading to an epithelial
to mesenchymal transition (EMT).6 Our results clearly show,
however, that Y654 phosphorylation by itself is not sufficient to
induce a migratory and invasive phenotype. Epithelial tissues
were properly formed in b-cateninE654/E654 embryos and also in
the intestinal tumours we did not observe enhanced invasiveness
of tumour cells. These observations do not exclude that Y654
phosphorylation contributes to the induction of EMT, but it will
most likely require the simultaneous activation of other EMT
inducers and the acquisition of additional mutations, for
example in KRAS and/or P53, to uncover its invasion-inducing
potential fully.
Based on our observations, we propose the following model
(figure 7). In cells that are exposed to extracellular Wnt ligands
Figure 5 Intestinal tumour incidence
of intestinal-specific Apc and Apc;YE
mice. (A) Total amount of tumours
detected in intestinal-specific Apc and
Apc;YE mice at the age of 8 months.
Black lines indicate the median amount
of tumours per genotype group.
*p¼0.02, ManneWhitney test. (B)
Percentage of intestinal tumours
detected in ileum, cecum or large
intestine of Apc and Apc;YE mice. (C)
Percentages of cells of tumours from
male Apc and Apc;YE mice showing
nuclear b-catenin. CIS, carcinoma in
situ. (D) Histological classification of
intestinal tumours of Apc and Apc;YE
mice according to Boivin et al.18 (E)
Average diameter in mm of all intestinal
tumours of Apc and Apc;YE mice.
*p¼0.022, **p¼0.0001, Student’s t-
test.
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or have generated a defect in the b-catenin degradation system,
b-catenin degradation is inhibited. Activation of RTK results in
phosphorylation of b-catenin at Y654 introducing a conforma-
tional change affecting proteineprotein interactions. This
reduces its affinity for the adherens complex, while it is simul-
taneously more accessible for additional phosphorylation, such
as phosphorylation of S675 by PKA. Next, phosphorylation of
both Y654 and S675 increases the recruitment of proteins
involved in the transcription machinery such as TCF4, CBP and
TBP,10 29 30 resulting in increased Wnt signalling. Overall, our
Figure 6 Phosphorylation at S675 in b-cateninE654 by protein kinase A (PKA). (AeC) Immunoblotting showing total b-catenin (bcat) and
phosphoS675 b-catenin (pS675) expression levels in total lysates of wild-type (YY), b-cateninY654/E654 (YE) and b-cateninE654/E654 (EE) mouse
embryonic fibroblasts (MEF) (A), embryos (B) and intestinal tumours from Apc and Apc;YE mice (C). Tubulin (TUB) expression levels were used as
a loading control. The relative expression levels were determined in three individual experiments and averaged. Numbers between brackets refer to the
number of independent cell lines used for each genotype. (D, E) MEF were treated with H89 (D) or forskolin (FSK) (E). Effects on PKA activity were
evaluated by determining the expression levels of phosphoCREB (pCREB, upper band; lower band is phosphoATF-1). Following treatment,
phosphoS675 b-catenin expression levels were determined and quantified. DMSO, dimethyl sulphoxide.
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data provide in-vivo evidence that in addition to genetic alter-
ations in the intestinal epithelium, the tumour stroma
substantially contributes to the development of intestinal cancer
through Y654 phosphorylation of b-catenin. Our results suggest
that treatment targeted at the tumour stroma, tyrosine kinases
and PKA may serve an efficient therapy strategy for patients
with intestinal or other cancers involving active Wnt signalling.
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Figure 7 Model of b-catenin Y654 phosphorylation contributing to Wnt
signalling. Upon activation of receptor tyrosine kinases (RTK), by
overexpression, activating mutations or (stromal) growth factors,
b-catenin is phosphorylated at Y654. This introduces a negative charge
that evokes a conformational change in the C-terminus of b-catenin,
affecting proteineprotein interactions. One of the affected interactions is
with cadherins for which the affinity is reduced, increasing the amount of
free b-catenin. Due to the open structure at the C-terminus, S675 is
more accessible for phosphorylation by protein kinase A (PKA). The
resulting C-terminal phosphorylated b-catenin enhances the recruitment
of proteins of the transcription machinery, such as TCF4, TBP and CBP.
Ultimately, this results in increased Wnt signalling contributing to
intestinal tumorigenesis.
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